

Sarah L Mackie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8370127/publications.pdf>

Version: 2024-02-01

95
papers

1,882
citations

377584

21
h-index

340414

39
g-index

101
all docs

101
docs citations

101
times ranked

1740
citing authors

#	ARTICLE	IF	CITATIONS
1	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2022, 49, 120.2-121.	1.0	0
2	Comment on: Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. <i>Rheumatology</i> , 2022, , .	0.9	1
3	A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PETâ€“CT images: Initial analysis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3315-3331.	1.4	7
4	Developing consensus in Histopathology: the role of the Delphi method. <i>Histopathology</i> , 2022, 81, 159-167.	1.6	10
5	P092â€“Patientsâ€™ perceptions of glucocorticoid therapy impact on health-related quality of life during treatment for rheumatic diseases: international development of a treatment-specific patient-reported outcome measure (the Steroid PRO). <i>Rheumatology</i> , 2022, 61, .	0.9	0
6	OA42â€“Evaluating the effects on a clinical service of introducing ultrasound for diagnosis of giant cell arteritis using Lean methodology. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	P026â€“Sugar rush: single-centre audit of screening and counselling for steroid-induced hyperglycaemia, based on the British Society for Rheumatology giant cell arteritis guideline. <i>Rheumatology</i> , 2022, 61, .	0.9	1
8	OA23â€“Patient-reported outcome measure for giant cell arteritis: cross-sectional validation study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
9	P126â€“GCA Hospital Standards (GHOST) - making a map of specialised services for the care of giant cell arteritis across England. <i>Rheumatology</i> , 2022, 61, .	0.9	0
10	Benchmarking tocilizumab use for giant cell arteritis. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	7
11	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	1.0	22
12	Outcomes Measured in Polymyalgia Rheumatica and Measurement Properties of Instruments Considered for the OMERACT Core Outcome Set: A Systematic Review. <i>Journal of Rheumatology</i> , 2021, 48, 883-893.	1.0	13
13	Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines. <i>Eye</i> , 2021, 35, 699-701.	1.1	5
14	Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice. <i>Lancet Rheumatology</i> , The, 2021, 3, e92-e94.	2.2	7
15	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	2.2	18
16	Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure. <i>Rheumatology</i> , 2021, 60, 4671-4680.	0.9	11
17	Genetically predicted serum urate levels have no causal role on depression or other psychiatric disorders. <i>Clinical Rheumatology</i> , 2021, 40, 3729-3733.	1.0	4
18	Ensuring high standards of British Society for Rheumatology clinical guidelines: reflections from the coalface. <i>Rheumatology</i> , 2021, 60, 2497-2499.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	1.6	13
20	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1320-1330.	1.6	25
21	Patient perceptions of physical activity after a diagnosis of Giant Cell Arteritis: analysis of multinational qualitative data. <i>Arthritis Care and Research</i> , 2021, , .	1.5	1
22	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1139-1145.	1.6	8
23	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210913.	1.0	2
24	Patient Reported Outcomes in Large Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2021, 23, 7.	2.1	2
25	Evaluating tertiary adrenal insufficiency in rheumatology patients on long-term systemic glucocorticoid treatment. <i>Clinical Endocrinology</i> , 2021, 94, 361-370.	1.2	13
26	Why clinicians should know about Mendelian randomization. <i>Rheumatology</i> , 2021, 60, 1577-1579.	0.9	16
27	The Patients' Perspective of Important Glucocorticoid Effects. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 232-238.	0.5	5
28	Scienced by blinding: ultrasound for giant cell arteritis. <i>Lancet Rheumatology</i> , The, 2021, 3, e824-e826.	2.2	1
29	COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. <i>BMC Nephrology</i> , 2021, 22, 359.	0.8	31
30	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	2.2	38
31	Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study. <i>Rheumatology</i> , 2020, 59, 319-323.	0.9	11
32	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e163-e164.	0.9	8
33	The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 996-1005.	1.6	14
34	Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001220.	1.2	29
35	Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. <i>JAMA Internal Medicine</i> , 2020, 180, 1295.	2.6	76
36	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e160-e160.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020, 47, 1379-1384.	1.0	10
38	British Society for Rheumatology guideline for diagnosis and treatment of giant cell arteritis. <i>Practical Neurology</i> , 2020, 20, 474-475.	0.5	3
39	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
40	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
41	What can negative temporal artery biopsies tell us?. <i>Rheumatology</i> , 2020, 59, 925-927.	0.9	8
42	Reduction in stiffness of proximal leg muscles during the first 6 months of glucocorticoid therapy for giant cell arteritis: A pilot study using shear wave elastography. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1891-1899.	0.9	4
43	267.â€fPATIENT PERCEPTIONS OF HEALTH RELATED QUALITY OF LIFE RELATED TO GIANT CELL ARTERITIS AND ITS TREATMENT: AN INTERNATIONAL QUALITATIVE STUDY. <i>Rheumatology</i> , 2019, 58, .	0.9	0
44	010â€fTemporal artery biopsy: audit, scoring and reporting. <i>Rheumatology</i> , 2019, 58, .	0.9	0
45	217â€fResults of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica. <i>Rheumatology</i> , 2019, 58, .	0.9	0
46	Characteristics of patients with giant cell arteritis who experience visual symptoms. <i>Rheumatology International</i> , 2019, 39, 1789-1796.	1.5	11
47	Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. <i>Journal of Rheumatology</i> , 2019, 46, 1179-1182.	1.0	8
48	Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1360-1364.	1.0	5
49	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1053-1058.	1.0	8
50	102.â€fPROPOSAL FOR A SYNOPTIC SYSTEM FOR REPORTING OF TEMPORAL ARTERY BIOPSIES. <i>Rheumatology</i> , 2019, 58, .	0.9	0
51	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1684-1686.	0.9	3
52	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1198-1201.	1.0	24
53	Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1374-1378.	1.0	6
54	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	0.9	17

#	ARTICLE	IF	CITATIONS
55	A probability score to aid the diagnosis of suspected giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 104-108.	0.4	12
56	Preliminary concurrent validity of the Fitbit-Zip and ActiGraph activity monitors for measuring steps in people with polymyalgia rheumatica. <i>Gait and Posture</i> , 2018, 61, 339-345.	0.6	17
57	Between Scylla and Charybdis: the toxicity of glucocorticoids in rheumatic disease. <i>Rheumatology</i> , 2018, 57, .	0.9	0
58	Cardiovascular risk factors are associated with the onset of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective cohort: EPIC-Norfolk study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
59	Comparative effectiveness of ¹⁸ F-FDG PET-CT and contrast-enhanced CT in the diagnosis of suspected large-vessel vasculitis. <i>British Journal of Radiology</i> , 2018, 91, 20180247.	1.0	14
60	Assessment of the face validity, feasibility and utility of a patient-completed questionnaire for polymyalgia rheumatica: a postal survey using the QQ-10 questionnaire. <i>Pilot and Feasibility Studies</i> , 2018, 4, 7.	0.5	6
61	A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1754-1758.	1.0	16
62	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
63	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1904-1910.	1.0	11
64	What is the impact of giant cell arteritis on patients' lives? A UK qualitative study. <i>BMJ Open</i> , 2017, 7, e017073.	0.8	24
65	A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 416-420.	0.5	21
66	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017, 44, 1515-1521.	1.0	33
67	Diagnostic delay for giant cell arteritis – a systematic review and meta-analysis. <i>BMC Medicine</i> , 2017, 15, 120.	2.3	63
68	Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221065.	0.2	2
69	Response to: "A relationship between extracapsular involvement and response to steroid treatment in polymyalgia rheumatica: too soon to conclude?" by Yang <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e17-e17.	0.5	1
70	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis" results from the IDEA study. <i>Rheumatology</i> , 2016, 55, 2181-2190.	0.9	21
71	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. <i>Journal of Rheumatology</i> , 2016, 43, 182-186.	1.0	25
72	Communication with patients before and after diagnostic tests. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 384-384.	1.1	0

#	ARTICLE	IF	CITATIONS
73	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	2.9	146
74	Curry-assisted diagnosis in the rheumatology clinic. <i>Oxford Medical Case Reports</i> , 2015, 2015, 297-299.	0.2	2
75	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
76	Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. <i>Rheumatology</i> , 2015, 54, 375-377.	0.9	15
77	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.5	220
78	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1808-1817.	0.5	74
79	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2465-2469.	1.0	33
80	HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 359-362.	0.9	24
81	Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR. <i>Journal of Rheumatology</i> , 2014, 41, 819-823.	1.0	28
82	Dealing with increased vascular risk and mortality in GCA. <i>Nature Reviews Rheumatology</i> , 2014, 10, 264-265.	3.5	11
83	P14. Investigations prior to temporal artery biopsy: a retrospective audit of compliance with the British Society for Rheumatology Guidelines for giant cell arteritis. <i>Rheumatology</i> , 2014, 53, i17-i17.	0.9	0
84	342.â€¦ Plasma Viscosity an Acceptable Substitute for Erythrocyte Sedimentation Rate for the Diagnosis of Giant Cell Arteritis?. <i>Rheumatology</i> , 2014, 53, i188-i188.	0.9	0
85	Polymyalgia rheumatica. <i>BMJ, The</i> , 2013, 347, f6937-f6937.	3.0	14
86	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1640-1645.	0.5	20
87	An overview of percutaneous renal biopsy. <i>Journal of Renal Nursing</i> , 2012, 4, 90-95.	0.1	0
88	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. <i>Rheumatology</i> , 2011, 50, 2014-2022.	0.9	31
89	Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. <i>Rheumatology</i> , 2010, 49, 716-722.	0.9	54
90	Renal nursing basics: oral hygiene and hair care. <i>Journal of Renal Nursing</i> , 2009, 1, 77-79.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Renal nursing basics: nail care and facial shaving. Journal of Renal Nursing, 2009, 1, 127-129.	0.1	1
92	An overview of vascular access part 1: early history. Journal of Renal Nursing, 2009, 1, 18-21.	0.1	0
93	The development of vascular access for haemodialysis, part 2. Journal of Renal Nursing, 2009, 1, 71-76.	0.1	0
94	Renal nursing basics: functions of the skin and bed bathing.. Journal of Renal Nursing, 2009, 1, 22-25.	0.1	0
95	Co-stimulatory blockade as therapy for rheumatoid arthritis. Current Rheumatology Reports, 2005, 7, 400-406.	2.1	12